Abstracts
Expand All

2020


Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)

Oncol 36[Suppl; abstr 557]. 2018.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2017


2016


• de Boer SM, Powell ME, Mileshkin LR, Katsaros D, Besseste P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles AW, Baron M-H, Kitchener HC, Nijman H, Kruitwagen RFPM, Jurgenliemk-Shultz IM, Nout RA, Smit VTHBM, Putter H, Creutzberg CL. Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-


- Strasser-Weippl K, Sudan G, Ramjeesingh R, Shepherd LE, O'Shaughnessy J, Chen BE, Parulekar WR, Liedke PER, Goss PE. Outcomes of invasive ductal (ID) or invasive lobular (IL) early stage breast cancer in women treated with anastrozole or exemestane
Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)


• Parimi S, Karachiwala H, Lin Y, Monzon JG, Tam VC, Chen EX, Dancey J, Tang PA. Critical assessment of phase 0 (Ph0) and window of opportunity (WOO) trials: Definitions and reporting. J Clin Oncol 33[Suppl; abstr e17710].


• Pennignt MG. Full report of the TROG 03.01, NCIC CTG ES2 multinational phase III study in advanced esophageal cancer comparing palliation of dysphagia and quality of life in patients treated with radiotherapy or chemoradiotherapy. J Clin Oncol 33[(Suppl 3; abstr 6)]. 2015.


metformin (Met) to placebo (Pl). J Clin Oncol 32:5s[ suppl; abstr 542]. 2014.


- Moy B, Tu D, Richardson H, Maunsell E, Goss PE. NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction. J Clin Oncol 31[suppl; abstr 6557], 2013.


- Renouf DJ, Parulekar W, Grigorieva J, Tu D, Moore MJ. Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial. J Clin Oncol 31[suppl; abstr 4061], 2013.


---

2012


- Liedke PER, Chavarri-Guerra Y, Shepherd LE, Tu D, Pritchard KI, Goss PE. Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17. J Clin Oncol 30[suppl, abstr 524], 2012.
- Pitz MW, MacNeil MV, Macdonald DR, Kakumanu AS, Thiessen B, Tsao MS, Kamel-


- Ringash J, Au H-J, Siu LL, Shapiro JD, Jonker DJ, Zalcberg JR, Moore MJ, Strickland AH, Koth R, Jeffery M, Alcindor T, Ng S, Salim M, Sabesan SS, Easaw JC, Shannon JA, El-Tahche F, Walters IB, Tu D, O’Callaghan CJ. Quality of life (QoL) assessment in patients (pts) with K-RAS wild-type (WT) chemotherapy refractory metastatic colorectal cancer (mCRC) treated with cetuximab (CET) plus brivanib alaninate (BRIV) or placebo: Results of the NCIC Clinical Trials Group and AGITG CO.20 trial. J Clin Oncol 30[suppl 4; abstr 542], 2012.


- Waldron JN, Parulekar W, O’Sullivan B, Chen BE, Montenegro A, Nabid A, Winquist E,


2011


• Basik M, Keilty D, Aleynikova O, Tu D, Li X, Shepherd LE, Bramwell V. Measurement of Pax2, TC21, CCND1, and RFS1 as predictive biomarkers for outcomes in the NCIC CTG MA.12 trial of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer. J Clin Oncol 29[Suppl; abstr 560], 2011.


• Cuffe S, Graziano S, Bourредjem A, Pignon J-P, Ezzalfani M, Seymour L, Strevel E, Burkes R, Capelletti M, Janne PA, Tsao MN, Shepherd FA. A pooled exploratory analysis of the impact of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy (ACT) in node negative (N0) non-small cell lung cancer (NSCLC). J Thoracic Oncol 6[6 suppl 2, abstr O42.01], S462, 2011.

Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)

suppl 2, abstr MO19.03], S641, 2011.


Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)


- Li X, Chen J, Wu Y, Tu D. Variable selections in the Cox proportional hazards model based on extended bayesian information criteria. 32nd Annual Conference of the International Society for Clinical Biostatistics, 2011.


- Meyer RM, Gospodarowicz M, Connors JM, Pearcey RG, Wells WA, Winter JN, Hornig SJ, Dar AR, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE. Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy


2010


- Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Thibodeau SN, Nair S. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: Results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 28[18s, abstr CRA3507], 2010.
• Chia SK, Ung K, Bramwell VH, Tu D, Perou CM, Ellis MJ, Bernard PS, Vickery T, Shepherd LE, Nielsen TO. Prognostic and predictive impact of biologic classification by qRT-PCR with a 50-gene subtype predictor for adjuvant tamoxifen in premenopausal breast cancer: Results from the NCIC CTG MA.12 randomized trial. J Clin Oncol 28[15s, abstr 508], 2010.
• Eisenhauer E. In search of intermediate endpoints. EORTC-NCI-AACR Symposium [abstr 29], 2010.


• Radich JP, Kopecky KJ, Kamel-Reid S, Stock W, Paietta E, Wadleigh M, Larson RA, Emanuel PD, Tallman MS, Lipton J, Couban S, Deininger MW, Appelbaum FR, Druker BJ. A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly


2010.


2009


- Craddock KJ, Buys TPH, Zhu CQ, Strumpf D, Pintillie M, Ding K, Seymour L, Jurisica I, Shepherd FA, Lam WL, Tsao M-S. High resolution genomic analysis of NSCLC reveals regions of DNA copy number gain that may be predictive of benefit from adjuvant chemotherapy. J Thoracic Oncol 4[9 suppl 1, abstr PD12.2.6], S580. 2009.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Kouroukis CT, Hafid T, Wong J, Kovacs MJ, Barr R, Findlay B, Shepherd L, Djurfeldt M, Ding K, Zhu L, Shustik C, Meyer R. Comorbidity, age and performance status are important predictors of outcome in older multiple myeloma patients treated with melphalan and corticosteroids; subgroup analysis from the National Cancer Institute of


- Palmer M, Broxterman J, Shepherd L, Parulekar W. Tracking patients on an intergroup oncology study. It's a snap! Clinical Trials 6, 536, 2009.


2008


- Bradbury PA, Tu D, Seymour L, Ng R, Zhu L, Isogai PK, Mittmann N, Evans WK, Shepherd FA, Leighl NB, on behalf of the NCIC CTG Working Group on Economic Analysis. Impact of clinical and molecular predictors of benefit from erlotinib in advanced


- Lerner SP, Stein JP, Stadler WM, Groshen S, Tuazon E, Skinner DG, Raghavan D, Esrig D, Steinberg G, Hall C, Cote R. Results of the p53 targeted therapy trial for
patients with organ confined node negative bladder cancer treated with radical cystectomy. Society of Urologic Oncology, 2008.


- Pollak MN, Chapman JW, Pritchard KI, Krook JE, Dhaliwal HS, Vandenberg TA, Norris BD, Whelan TJ, Wilson CF, Shepherd LE. NCIC-CTG MA14 trial: Tamoxifen (tam) vs. tam + octreotide (oct) for adjuvant treatment of stage I or II postmenopausal breast


- Schell AJ, Young I, Hansen C, Chi KN, Taylor S. BRAF mutation status and growth factor receptor expression do not predict baseline factors or outcome in hormone refractory prostate carcinoma. United States and Canadian Academy of Pathology, 2008.


- Vergote I, Tropé CG, Amant F, Kristensen GB, Sardi JE, Ehlen T, Johnson N, Verheijen


- Au H-J, Brundage M, Ringash J, Bezjak A, Palmer M, Richardson H, Lee CW, Maunsell


trial in prostate cancer of radiotherapy timing and hormone therapy duration after radical prostatectomy (MRC PR10, NCIC PR13, ISRCTN40814031). NCRI United Kingdom, 2007.


Tu D. Identification of patients who will benefit from a treatment based on their genetic profiles: Some examples and statistical issues. Workshop on Statistical Analysis of High-Throughput Genetic Data, 2007.


Chen CI, Kouroukis T, White D, Voralia M, Stadtmauer E, Wright J, Powers J, Eisenhauer E. Bortezomib is active in Waldenström's Macroglobulinemia (WM) - Results


• O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman DG, Bramwell VH, Andrulis I, Pritchard KI. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Breast Cancer Research and Treatment 100[Suppl 1], S18, 2006.
• O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman DG, Bramwell VH, Andrulis IL, Pritchard KI. Prognostic and predictive value of topoisomerase II alpha in a


maintaining hemoglobin = 120 G/L with erythropoietin during chemoradiation for cervical cancer. Int J Gynecol Cancer 16[3], 603-604, 2006.


2005


- Goss PE, Ingle J, Tu D, Shepherd L, Pater J. NCIC CTG MA17: Disease free survival
according to estrogen receptor and progesterone receptor status of the primary tumor. 


Li D. Determinants of sample size and power in equivalence trials that compare binomial outcomes. Clinical Trials 2[Suppl 1], S59, 2005.

Li D. Can more frequent regular group sequential tests help to make an earlier conclusion in clinical trials? A retrospective evaluation. Clinical Trials 2[Suppl 1], 2005.


Messerschmidt T, Koski B. Integrating SOPs into a comprehensive website document management system. Clinical Trials 2[Suppl 1], S50, 2005.


2005.

- Tu D. Nonparametric estimate and confidence intervals for the hazard ratio based on censored data. Clinical Trials 2[Suppl 1], S36, 2005.

2004

- Chi K, Eisenhauer E, Fazli L, Jones EC, Powers J, Hurtado-Coll A, Goldberg L, Gleave ME. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2’methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer...
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Ding K. Point estimate following group sequential tests. ENAR Int Biometric Soc, 2004.


Ehrenberger H, Bacon M, Burkes K, Lillington L, Ward K, Zimmerman J. The
development of a virtual work group of the ONS Clinical Trials Nurses Special Interest Group: Keys to productivity. Oncology Nursing Society, 2003.


2002

- Bezjak A, Perrone F, Gallo C, Hirsh V, Seymour L, Plantedosi F, Shepherd F, Robbiati


Madarnas Y, Fine S, Sawka C, Shepherd L, Tannock I, Tu D, Levine M. Body size,


• Crump M, Tu D, Shepherd L, Levine E, Bramwell V, Pritchard K. Risk of acute leukemia


Abstracts Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)


2000


1999


1998


Pater J, Bezjak A, Osoba D, Zee B, Palmer M. Quality of life as an endpoint in NCIC...
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1997


Dent S, Klaassen D, Pater J, Zee B, Whitehead M. Update of second primary malignancies and treatment results in women with early stage ovarian cancer.


1996

daunorubicin and cytosine arabinoside as induction therapy and all-trans retinoic acid versus observation as maintenance therapy for patients with previously untreated acute promyelocytic leukemia. Blood (ASH Annual Meeting Abstracts) 86[10 Suppl 1], 1996.

- Zee B. Phase II design for cancer clinical trials using multivariate endpoints. Biometric Society ENAR, 1996.

1995

- Latreille J, Johnston D, Laberge F, Stewart D, Rusthoven J, Nishimura L, Pater J, Zee B.
Use of granisetron and dexamethasone on day 2-7 following high dose cisplatin. Supportive Care in Cancer 3(5), 339, 1995.


- Lofters C, Zee B. Adding 5HT3 antagonists to dexamethasone after 24 hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Eur.J.Can. 31A(suppl.5), 255, 1995.


- Pater J, Zee B, Lofters W, Osoba D, Warr D, Palmer M, Chin C, Dempsey E. Effective


1994


- Eisenhauer E, Bacon M, Atri M, Lemort M, Nolan R, Petroons P, Sauerbrei E, Florczyk
Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)


- Zee B, James K, Johnston D. Design and analysis of late randomization trials:
information from time to first response in multiple myeloma. Joint ASA and Biometric

1993

- Bacon M. Central radiology review of responders. Tumour Measurement, Response
  Assessment Symposium, 1993.
- Belch A, Osterwalder B, Eisenhauer E, Muldal A, Skingley L, Browman G, O'Reilly S,
  Michal S. Phase II study of subcutaneous recombinant human interleukin-2 (rHu IL-2)
  and interferon alfa-2a (rHu IFN alfa-2a) in previously treated patients with multiple
  myeloma. A study of the National Cancer Institute of Canada Clinical Trials Group A
  study of the NCIC Clinical Trials Group. Congress of Cytokines and Growth Factors in
- Brundage M, Pater J, Zee B. Assessing the reliability of two treatment toxicity scales:
  D, Stewart D, Schold C, Wainman N, Eisenhauer E. Phase II study of chemotherapy for
  1993.
- Cormier Y, Eisenhauer E, Gregg R, Ayoub J, Goss G, Stewart D, Muldal A, Tarasoff P.
  Gemcitabine: an active new agent in patients with previously untreated small cell lung
- Eisenhauer E, Ten Bokkel-Huinink W, Swenerton K, Mangioni C, van der Burg M, Kerr I,
  European-Canadian trial of high vs low dose and short vs long infusion in ovarian
- Grever M, Kopecky K, Head D, Foucar K, Cassileth P, Golomb H, Habermann T, Rai K,
  Eisenhauer E, Appelbaum F, Cheson B. A randomized comparison of deoxycoformycin
  versus alpha-2a interferon in previously untreated patients with hairy cell leukemia: an
  updated report on the NCI-sponsored intergroup study (SWOG, ECOG, CALGB, NCIC
- Latreille J, Stewart D, Laberge F, Hoskins P, Rusthoven J, McMurtie E, Warr D, Yelle L,
  Walde D, Shepherd F, Dhaliwal H, Findlay B, Mee D, Pater J, Zee B, Johnston D.
  Dexamethasone improves the efficacy of granisetron in the first 24 hours following high
- Latreille J, Stewart D, Laberge F, Hoskins P, Rusthoven J, McMurtie E, Warr D, Yelle L,
  Walde D, Shepherd F, Dhaliwal H, Findlay B, Mee D, Pater J, Zee B, Johnston D.
  Dexamethasone improves the efficacy of granisetron in the first 24 hours following high
- Macdonald D, Cairncross G, Eisenhauer E. NCIC CTG phase II study of topotecan for
  malignant glioma. International Conference of Brain Tumour Research and Therapy,
  1993.
  D, Stewart D, Schold C, Wainman N, Eisenhauer E. NCIC CTG phase II study of
  chemotherapy for anaplastic oligodendroglioma. International Conference of Brain
Tumour Research and Therapy, 1993.

- Paul N. The success of clinical trials depends on good communication. Joint meeting of EORTC SGDM and BODMA, 1993.


Pater J, Niezgoda H, Zee B. Validation of the EORTC-QLC -- a comparison with four other instruments in a heterogenous group of cancer patients. Ann.Oncol. 3(Suppl.5), 175, 1992.


Zee B. One-sided test for clinical trials with group sequential design that allow early
Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)


1991


304, 1990.


1989


• Palmer M, Pater J. Comparison of errors in body surface area and initial doses in five clinical trials (C0.2, C0.3, HD.4, MA.4, OV.8). Controlled Clin.Trials 10(3), 351, 1989.


1988


1987


1986

- Wallenstein S, Patel HI, Willan A. Use of baseline values in the two period two treatment crossover design. Biometric Society ENAR, 1986.

1985


1984


1983


1981
